HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Steroid Injections May Damage Hip and Knee Joints

By HospiMedica International staff writers
Posted on 26 Oct 2019
Image: Progressive loss of acetabular and femoral cartilage and subchondral cystic changes after IACS (Photo courtesy of Ali Guermazi Radiology).
Image: Progressive loss of acetabular and femoral cartilage and subchondral cystic changes after IACS (Photo courtesy of Ali Guermazi Radiology).
A new study suggests that intra-articular corticosteroid (IACS) injections could lead to accelerated joint destruction, and may hasten the need for total hip and knee replacements.

Researchers at Boston University School of Medicine (BUSM; MA, USA), the French National Institute of Sports (INSEP; Paris, France), and Friedrich-Alexander University Erlangen-Nürnberg (FAU; Germany) undertook a review of the existing literature in order to describe observed adverse joint events following the administration of IACS injections to treat osteoarthritis (OA) pain, and also to provide an outlook on how this may affect clinical practice.

The researchers identified four main adverse outcomes: accelerated osteoarthritis progression with loss of the joint space, osteonecrosis complications, subchondral insufficiency fractures (stress fractures beneath the cartilage), and rapid joint destruction, including bone loss. They thus recommend careful scrutiny of patients with mild or no OA on X-rays who are referred for IASC, especially when the pain reported is disproportionate to imaging findings, and that patients need to be told of the potential consequences of a corticosteroid injection before they receive it. The study was published on October 15, 2019, in Radiology.

“Intra-articular joint injection of steroids is a very common treatment for osteoarthritis-related pain, but potential aggravation of pre-existing conditions or actual side effects in a subset of patients need to be explored further to better understand the risks associated,” said lead author Professor Ali Guermazi, MD, PhD, of BUMC. “We've been telling patients that even if these injections don't relieve your pain, they're not going to hurt you. But now we suspect that this is not necessarily the case.”

OA is a group of mechanical abnormalities involving degradation of joints, including articular cartilage and subchondral bone. Symptoms may include joint pain, tenderness, stiffness, locking, and sometimes an effusion. A variety of causes--hereditary, developmental, metabolic, and mechanical deficits--may initiate processes leading to loss of cartilage. As a result of decreased movement secondary to pain, regional muscles may atrophy, and ligaments may become more lax. OA of the knee affects about 250 million people worldwide (3.6% of the population).

Related Links:
Boston University School of Medicine
French National Institute of Sports
Friedrich-Alexander University Erlangen-Nürnberg



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Hemostatic Agent
HEMOBLAST Bellows

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more